Activation of FGF19 reduces bile acid synthesis, potentially mitigating lipid dysregulation in NASH patients.[22] OCA also inhibits the transforming growth factor-β gene, influences extracellular matrix reorganization, and suppresses hepatic stellate cell activation. Here, FGF19 is linked to metabolic dysfunction-associated steatohepatitis.